← All supplements
Limited evidenceHeart & metabolic

Oyster Mushroom

Marketed as a natural source of lovastatin and beta-glucans for cholesterol. The two best-controlled human trials both failed to lower LDL or non-HDL cholesterol.

Evidence last reviewed: August 2026

What the science says

  • LDL cholesterol Limited evidence

    A double-blind randomised controlled trial in 46 adults with moderately elevated LDL gave 8.4 g/day of oyster mushroom powder (3 g beta-glucans) for 4 weeks and found no effect on LDL, other lipids or apolipoproteins. A post-hoc analysis suggested reduced cholesterol absorption markers in women only.

  • Lipids in a clinical population Limited evidence

    An open-label 8-week study in 20 HIV patients with antiretroviral-induced hyperlipidaemia found 15 g/day of freeze-dried Pleurotus ostreatus did not lower non-HDL cholesterol; only 3 of 20 achieved a clinically meaningful decline.

  • Visceral fat and metabolic markers Limited evidence

    A small community study in rural Mexico reported reductions in visceral fat and blood lipids with dietary oyster mushroom, but it was not a rigorous placebo-controlled design and stands against the two negative controlled trials.

Dosage & safety

Studied doseTrials used 8–15 g/day of dried mushroom powder for 4–8 weeks. Capsule products supply far less than this, typically 500–1000 mg per serving.
SafetySafe as a food. Spores can trigger asthma-like hypersensitivity pneumonitis in growers and heavy handlers of dry powder. Mushrooms concentrate heavy metals from their substrate, so sourcing matters. Anyone relying on it instead of a prescribed statin is taking a real risk, as the trial data do not support cholesterol lowering.

Scientific references

Where to buy

Referral link — this site may earn a commission on purchases.

Related in Heart & metabolic